NewAmsterdam Pharma Files 8-K

Ticker: NAMSW · Form: 8-K · Filed: Mar 4, 2024 · CIK: 1936258

Newamsterdam Pharma CO N.V. 8-K Filing Summary
FieldDetail
CompanyNewamsterdam Pharma CO N.V. (NAMSW)
Form Type8-K
Filed DateMar 4, 2024
Risk Levellow
Pages2
Reading Time2 min
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 8-k, regulation-fd

Related Tickers: NAMS

TL;DR

NAMS filed an 8-K on 3/4/24, check for updates.

AI Summary

NewAmsterdam Pharma Co N.V. filed an 8-K on March 4, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing pertains to the company's operations and financial reporting as of that date. No specific financial figures or material events were detailed in the provided excerpt.

Why It Matters

This filing indicates that NewAmsterdam Pharma Co N.V. is providing updated information to the SEC, which could include material disclosures relevant to investors.

Risk Assessment

Risk Level: low — The provided excerpt is a standard SEC filing notification without specific material events or financial data that would indicate immediate risk.

Key Players & Entities

FAQ

What specific information is being disclosed in this 8-K filing?

The filing indicates it includes a Regulation FD Disclosure and Financial Statements and Exhibits, but the specific details are not provided in the excerpt.

When was this 8-K filed?

The 8-K was filed on March 4, 2024.

What is the Commission File Number for NewAmsterdam Pharma Co N.V.?

The Commission File Number is 001-41562.

What is the principal executive office address for NewAmsterdam Pharma Co N.V.?

The principal executive office is located at Gooimeer 2-35, Naarden, The Netherlands, 1411 DC.

What is the Standard Industrial Classification code for NewAmsterdam Pharma Co N.V.?

The Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 571 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-03-04 08:06:24

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. EXHIBIT NUMBER EXHIBIT DESCRIPTION 99.1 NewAmsterdam Pharma Company N.V. Corporate Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NewAmsterdam Pharma Company N.V. By: /s/ Michael Davidson Michael Davidson Chief Executive Officer Dated: March 4, 2024

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing